The digital health app Miiskin has announced the introduction of a new feature for sizing birthmarks.
The skin check app, headquartered in Denmark, enables patients to use augmented reality technology to check whether their moles have changed.
The birthmark sizing feature requires users to photograph their birthmark next to a reference object such as a coin to measure and record the size of the lesion. This helps users identify two of the five signs on the ABCDE tracker, a system recommended by doctors.
Users can also take pictures of moles, including size, and monitor changes in shape and color over time to see if the mole is developing, which is an “E” warning sign on the tracker.
WHY IT IS IMPORTANT
According to the Skin Cancer Foundation, 80% of melanomas appear as new spots or birthmarks. Dermatologists believe that more than half the time people notice the first signs of skin cancer in themselves, so skin self-exams are crucial for early detection.
When doing skin self-exam, the size and appearance of birthmarks are essential elements to evaluate when looking for possible signs of melanoma. However, slight changes in size may not be noticeable to the naked eye or if the mole is in an area that is difficult to access.
Miiskin’s technology is designed to help users identify warning signs so they can consult a dermatologist for medical evaluation and treatment.
THE GREATER CONTEXT
Last year, Miiskin introduced automatic skin imaging, which allows people to take full-body photos of their skin through their app to facilitate skin cancer self-exam.
Also in 2020, Miiskin became one of the first skin checking apps to be listed in the EMIS App Library. Recently, Miiskin was named one of the top five best practices apps by ORCHA, the organization responsible for evaluating digital health apps for the NHS.
At the beginning of the year, the Swiss startup OnlineDoctor raised 5 million euros as part of Series A funding for its web-based teledermatology platform, which provides patients with a specialized diagnosis and recommendations for action for their skin problem within 48 hours.
Meanwhile, UK medical device company Moletest (Scotland) Ltd is offering primary care physicians its Nomela screening test for skin lesions suspected of having melanoma.
ON THE RECORD
Jon Friis, Founder and CEO of Miiskin, said, “This type of technology has never been openly available to the public for their own use.
“We’ve combined Apple’s latest machine learning, computer vision, and augmented reality technologies to bring this directly to patients and further assist them in skin self-exam, a critical process in the early detection of skin cancer.”
Dr. Anton Alexandroff, Consultant Dermatologist and Spokesperson for the British Skin Foundation, said, “Providing this type of technology to patients will really help them with their skin examination process. Not only does it help raise awareness of the importance of self-exam, it also helps them identify the key factors to look out for when examining their skin. “